Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Office Depot Inc. (NYSE: ODP) shares declined 2.83 percent to close at $4.12 a share Wednesday The stock traded between $3.93 and $4.16 on volume of 16.06 million shares traded. Office retailers were dragged down by Staples’ disappointing quarterly results. Shares of Office Depot have gained approximately 25.0 percent year-to-date.
Get more information on Office Depot and free access to the in-depth equity report at:
www.FiveStarEquities.com/ODP
SGOCO Group Ltd. (NASDAQ: SGOC) shares soared 34.88 percent to close at $3.79 a share Wednesday. The stock traded between $3.38 and $4.57 on volume of 5.95 million shares traded. The company reported a net income of $3.4 million for the second quarter of 2013, an increase of 175.7 percent when compared to the year ago quarter.
Get more information on SGOCO Group and free access to the in-depth equity report at:
www.FiveStarEquities.com/SGOC
Sunshine Heart Inc. (NASDAQ: SSH) shares surged 14.43 percent to close at $10.47 a share Wednesday. The stock traded between $9.14 and $11.15 on volume of 833,856 shares traded. The company has recently announced collaboration with St. Paul-based Minnetronix for Sunshine’s fully-implantable C-Pulse device under development. Shares of Sunshine Heart have gained approximately 72.0 percent year-to-date.
Get more information on Sunshine Heart and free access to the in-depth equity report at:
www.FiveStarEquities.com/SSH
Stemline Therapeutics Inc. (NASDAQ: STML) shares declined 8.98 percent to close at $31.43 a share Wednesday. The stock traded between $29.55 and $34.36 on volume of 410,632 shares traded. The company recently presented at the 2013 Wedbush Life Sciences Conference on August 14th. Shares of Stemline Therapeutics have gained approximately 157.0 percent year-to-date.
Get more information on Stemline Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/STML
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com